about
Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazinesImpact of the emergence of designer drugs upon sports doping testingEmerging drugs of abuse: current perspectives on substituted cathinones.Simultaneous determination of N-benzylpiperazine and 1-(3-trifluoromethylphenyl)piperazine in rat plasma by HPLC-fluorescence detection and its application to monitoring of these drugs.Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse.Prevalence of new psychoactive substances: A retrospective study in hair.UPLC/ESI-MS/MS-based determination of metabolism of several new illicit drugs, ADB-FUBINACA, AB-FUBINACA, AB-PINACA, QUPIC, 5F-QUPIC and α-PVT, by human liver microsome.Benzylpiperazine: a drug of abuse?Toxicity from the recreational use of 1-benzylpiperazine.Using cheminformatics to predict cross reactivity of "designer drugs" to their currently available immunoassays.In vitro approaches to studying the metabolism of new psychoactive compounds.Current status of hyphenated mass spectrometry in studies of the metabolism of drugs of abuse, including doping agents.Current applications of high-resolution mass spectrometry in drug metabolism studies.Update on 1-benzylpiperazine (BZP) party pills.Recent developments in urinalysis of metabolites of new psychoactive substances using LC-MS.In vitro hepatotoxicity of 'Legal X': the combination of 1-benzylpiperazine (BZP) and 1-(m-trifluoromethylphenyl)piperazine (TFMPP) triggers oxidative stress, mitochondrial impairment and apoptosis.Severe paramethoxymethamphetamine (PMMA) and paramethoxyamphetamine (PMA) outbreak in Israel.Cognitive functioning associated with stimulant use in patients with non-affective psychosis, their unaffected siblings and healthy controls.Screening of stimulants including designer drugs in urine using a liquid chromatography tandem mass spectrometry system.Driving under the influence of amphetamine-like drugs.Colorimetric detection and chromatographic analyses of designer drugs in biological materials: a comprehensive reviewToxicology of Specific Substances
P2860
Q24631675-EFF1361C-F96A-4D1C-A6AF-879CE77D79BCQ28255977-1DD450BE-505A-4FA8-8788-6405FD46EDF2Q33706892-06DE7C7B-BD72-4906-9865-4C33869746D4Q33841160-A744A089-EE9B-4583-A38B-8EDE891700ACQ34165511-371EBC12-EC54-4852-9797-99416416F1ECQ34270004-A4056605-532D-41CA-8753-51EF5522D942Q34421396-8DED4C72-E9D3-4DEB-8D69-1CBE68E1E8D3Q34580800-F56C5BBE-5DB7-4F18-8444-63E3B821EB5AQ34839105-2114C6D6-909D-4D91-A8B9-46F92D3DEE67Q35172366-AA0475AE-AFF2-4EAF-B22C-27CDCBEFA98DQ37889234-3325E244-C516-4543-8B99-B59605DC2C1DQ37922114-93AE4996-39C5-4227-9E89-483049B5B13BQ37986333-1CE5E759-C45C-4BB8-B703-9B487DCEFA0BQ38107787-E0547614-8E2C-4BF9-88F2-0EF36C6E7D1BQ38260819-673B7AEA-F852-4E64-AD92-055F0A368801Q39643944-1AB5B832-A48E-4083-B413-2C2B1984E0D0Q45196224-814E7975-31E4-4995-9A31-8F363953FB6FQ47945952-B49EB5E6-3D4A-4A71-B4FA-F3C2921C0E7EQ48099182-249CFB2E-3238-4A0F-9C01-AAF2887A8E99Q48187063-BCB09299-0B6C-4B3B-B0E1-17EAE67E682AQ56763257-108C5857-6B8F-4E1D-B3B2-1E527F380A32Q57986556-DBC8ED3B-3207-4601-8016-28BF338B83B5
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Metabolism of designer drugs of abuse
@ast
Metabolism of designer drugs of abuse
@en
Metabolism of designer drugs of abuse
@nl
type
label
Metabolism of designer drugs of abuse
@ast
Metabolism of designer drugs of abuse
@en
Metabolism of designer drugs of abuse
@nl
prefLabel
Metabolism of designer drugs of abuse
@ast
Metabolism of designer drugs of abuse
@en
Metabolism of designer drugs of abuse
@nl
P356
P1476
Metabolism of designer drugs of abuse
@en
P2093
Roland F Staack
P304
P356
10.2174/1389200054021825
P407
P577
2005-06-01T00:00:00Z